3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Small Cell Lung Carcinoma
13
Carcinoma, Non-Small-Cell Lung
10
Lung Neoplasms
9
Stomach Neoplasms
3
Ovarian Neoplasms
3
Mesothelioma
3
Breast Neoplasms
3
Triple Negative Breast Neoplasms
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Thymoma
1
SCLC,Extensive Stage
1
SCLC
1
Prostatic Neoplasms
1
Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma
1
Non-small-cell Lung Cancer Patients
1
Non-small Cell Lung Cancer NSCLC
1
Non-small Cell Lung Cancer Metastatic
1
Neuroendocrine Tumors
1
Neoplasm Metastasis
1
Mesothelioma, Malignant
1
Melanoma
1
Fallopian Tube Neoplasms
1
Endometrial Neoplasms
1
EGFR-Mutated Non-Small-Cell Lung Carcinoma
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Advanced Solid Tumor
1
Interventions
pembrolizumab
4
Pemetrexed
4
Carboplatin
4
Gemcitabine
3
Bevacizumab
3
tusamitamab ravtansine
2
Vinorelbine
2
Ramucirumab
2
Erlotinib Hydrochloride
2
Docetaxel
2
1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine
2
vistusertib
1
vandetanib
1
telomerase reverse transcriptase p572Y, human
1
spartalizumab
1
sotorasib
1
sintilimab
1
olaparib
1
necitumumab
1
icotinib
1
durvalumab
1
dacomitinib
1
capivasertib
1
aumolertinib
1
Radiosurgery
1
Platinum
1
Paclitaxel
1
MLN 8237
1
LY3023414
1
Injections
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Non-small Cell Lung Cancer Metastatic
×
olaparib
×
Thoracic
×
Clear all
NCT02117167
2024-01-10
SAFIR02_Lung
UNICANCER
Phase 2
Completed
999 enrolled